135 related articles for article (PubMed ID: 29441441)
21. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
[TBL] [Abstract][Full Text] [Related]
23. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers.
Vos S; Moelans CB; van Diest PJ
Breast Cancer Res; 2017 May; 19(1):64. PubMed ID: 28569220
[TBL] [Abstract][Full Text] [Related]
24. Risk modeling in breast cancer.
Euhus D
Breast J; 2004; 10 Suppl 1():S10-2. PubMed ID: 14984482
[TBL] [Abstract][Full Text] [Related]
25. BRCA1/2 germline mutations and their clinical importance in Turkish breast cancer patients.
Cecener G; Egeli U; Tunca B; Erturk E; Ak S; Gokgoz S; Tasdelen I; Tezcan G; Demirdogen E; Bayram N; Avci N; Evrensel T
Cancer Invest; 2014 Oct; 32(8):375-87. PubMed ID: 24884828
[TBL] [Abstract][Full Text] [Related]
26. Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.
van Harssel JJ; van Roozendaal CE; Detisch Y; Brandão RD; Paulussen AD; Zeegers M; Blok MJ; Gómez García EB
Fam Cancer; 2010 Jun; 9(2):193-201. PubMed ID: 19949876
[TBL] [Abstract][Full Text] [Related]
27. Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers.
Streff H; Profato J; Ye Y; Nebgen D; Peterson SK; Singletary C; Arun BK; Litton JK
Oncologist; 2016 Jul; 21(7):869-74. PubMed ID: 27306910
[TBL] [Abstract][Full Text] [Related]
28. Are BRCA1 and BRCA2 gene mutation patients underscreened for pancreatic adenocarcinoma?
Roch AM; Schneider J; Carr RA; Lancaster WP; House MG; Zyromski NJ; Nakeeb A; Schmidt CM; Ceppa EP
J Surg Oncol; 2019 May; 119(6):777-783. PubMed ID: 30636051
[TBL] [Abstract][Full Text] [Related]
29. Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
Rao NY; Hu Z; Li WF; Huang J; Ma ZL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Feb; 113(3):467-77. PubMed ID: 18343994
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of pancreaticobiliary cancers in Irish families with pathogenic BRCA1 and BRCA2 variants.
Power R; Leavy C; Nolan C; White N; Clarke R; Cadoo KA; Gallagher DJ; Lowery MA
Fam Cancer; 2021 Apr; 20(2):97-101. PubMed ID: 32918181
[TBL] [Abstract][Full Text] [Related]
31. Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Weitzel JN; Lagos VI; Cullinane CA; Gambol PJ; Culver JO; Blazer KR; Palomares MR; Lowstuter KJ; MacDonald DJ
JAMA; 2007 Jun; 297(23):2587-95. PubMed ID: 17579227
[TBL] [Abstract][Full Text] [Related]
32. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
[TBL] [Abstract][Full Text] [Related]
34. Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: a retrospective study in a sample of Italian cancer genetics clinics.
Varesco L; Viassolo V; Viel A; Gismondi V; Radice P; Montagna M; Alducci E; Della Puppa L; Oliani C; Tommasi S; Caligo MA; Vivanet C; Zuradelli M; Mandich P; Tibiletti MG; Cavalli P; Lucci Cordisco E; Turchetti D; Boggiani D; Bracci R; Bruzzi P; Bonelli L
Breast; 2013 Dec; 22(6):1130-5. PubMed ID: 24011770
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Hartman AR; Kaldate RR; Sailer LM; Painter L; Grier CE; Endsley RR; Griffin M; Hamilton SA; Frye CA; Silberman MA; Wenstrup RJ; Sandbach JF
Cancer; 2012 Jun; 118(11):2787-95. PubMed ID: 22614657
[TBL] [Abstract][Full Text] [Related]
36. Ductal carcinoma in situ in BRCA mutation carriers.
Hwang ES; McLennan JL; Moore DH; Crawford BB; Esserman LJ; Ziegler JL
J Clin Oncol; 2007 Feb; 25(6):642-7. PubMed ID: 17210933
[TBL] [Abstract][Full Text] [Related]
37. BRCA1 and BRCA2 genetic test in high risk patients and families: counselling and management.
Marchina E; Fontana MG; Speziani M; Salvi A; Ricca G; Di Lorenzo D; Gervasi M; Caimi L; Barlati S
Oncol Rep; 2010 Dec; 24(6):1661-7. PubMed ID: 21042765
[TBL] [Abstract][Full Text] [Related]
38. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
39. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
40. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer.
Dagan E
Genet Test; 2008 Jun; 12(2):267-71. PubMed ID: 18439109
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
